The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation

Transplantation

Volumn 87, Issue 10, 2009, Pages 1541-1548

  Danziger Isakov, Lara A ^a,m   Worley, Sarah ^a   Michaels, Marian G ^b   Arrigain, Susana ^a   Aurora, Paul ^c   Ballmann, Manfred ^d   Boyer, Debra ^e   Conrad, Carol ^f   Eichler, Irmgard ^g   Elidemir, Okan ^h   Goldfarb, Samuel ⁱ   Mallory, George B ^h   Mogayzel, Peter J ^j   Parakininkas, Daiva ^k   Solomon, Melinda ^l   Visner, Gary ^e   Sweet, Stuart ^m   Faro, Albert ^m  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HARVARD UNIVERSITY   (United States)

^f STANFORD UNIVERSITY   (United States)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h TEXAS CHILDREN S HOSPITAL   (United States)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j DEPARTMENT OF PATHOLOGY   (United States)

^k CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^l HOSPITAL FOR SICK CHILDREN   (Canada)

^m ST LOUIS CHILDREN S HOSPITAL   (United States)

more..

Author keywords

Cytomegalovirus; Lung transplantation; Pediatrics

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEWBORN; NONHUMAN; PEDIATRIC SURGERY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS CULTURE;

ACUTE DISEASE; BRONCHIOLITIS OBLITERANS; CHILD; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EUROPE; FEMALE; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUNG TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; NORTH AMERICA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS;

EID: 67649576904     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a492e8     Document Type: Article

References (26)

1. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753.
2. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: Study of risk factors. J Heart Lung Transplant 2001; 20: 1274.
3. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46: 831.
4. Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006; 81: 1415.
5. Maurer JR, Tullis DE, Scavuzzo M, et al. Cytomegalovirus infection in isolated lung transplantations. J Heart Lung Transplant 1991; 10(5 Pt 1): 647.
6. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washing- ton University Lung Transplant Group. Am Rev Respir Dis 1993; 147: 1017.
7. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86.
8. Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant1991; 10(5 Pt 1): 638.
9. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention ofCMVinfection following lung transplantation. Am J Transplant 2004; 4: 1635.
10. Danziger-Isakov LA, Delamorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung transplant recipients. Transplantation 2003; 75: 1538.
11. Metras D, Viard L, Kreitmann B, et al. Lung infection in pediatric lung transplant: Experience in 49 cases. Europ J Cardiothorac Surg 1999; 15: 490.
12. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
13. Ljungman P, Griffiths P, Paya C. Definition of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
14. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of the nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713.
15. Berry GJ, Brunt EM, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 593.
16. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation of the classification of pulmonary allograft rejection: Lung rejection study group. J Heart Lung Transplant 1996; 15: 1.
17. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
18. Danziger-Isakov LA, Worley S, Arrigain S, et al. Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation. J Heart Lung Transplant 2008; 27: 655.
19. Opelz G, Döhler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
20. Kranz B, Vester U, Wingen AM, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008; 12: 474.
21. Kamar N, Mengelle C, Esposito L, et al. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J Med Virol 2008; 80: 1012.
22. Kuypers DR, Evenepoel P, Maes BD, et al. Role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. Transplant Proc 2002; 34: 1164.
23. Jorge S, Guerra J, Santana A, et al. Mycophenolate mofetil: Ten years' experience of a renal transplant unit. Transplant Proc 2008; 40: 700.
24. Steininger C, Kundi M, Kletzmayr J, et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908.
25. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971.
26. Singh N. Cytomegalovirus infection in solid organ transplant recipients: New challenges and their implications for preventive strategies. J Clin Virol 2006; 35: 474.